Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more
Karyopharm Therapeutics Inc (KPTI) - Total Liabilities
Latest total liabilities as of September 2025: $365.49 Million USD
Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has total liabilities worth $365.49 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Karyopharm Therapeutics Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Karyopharm Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Karyopharm Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nabors Energy Transition Corp. II Class A Ordinary Shares
NASDAQ:NETD
|
USA | $14.15 Million |
|
Priner Serviços Industriais S.A
SA:PRNR3
|
Brazil | R$1.07 Billion |
|
Prime Mining Corp
OTCQX:PRMNF
|
USA | $1.56 Million |
|
Acres Commercial Realty Corp
NYSE:ACR
|
USA | $1.25 Billion |
|
Genome & Company
KQ:314130
|
Korea | ₩41.38 Billion |
|
1Stdibs.Com Inc
NASDAQ:DIBS
|
USA | $38.53 Million |
|
Garofalo Health Care S.p.A
F:GHC
|
Germany | €507.83 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Karyopharm Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Karyopharm Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual total liabilities of Karyopharm Therapeutics Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $401.34 Million | +14.53% |
| 2024-12-31 | $350.44 Million | -6.96% |
| 2023-12-31 | $376.64 Million | +0.48% |
| 2022-12-31 | $374.83 Million | -2.64% |
| 2021-12-31 | $384.98 Million | +46.66% |
| 2020-12-31 | $262.50 Million | +7.06% |
| 2019-12-31 | $245.19 Million | +55.16% |
| 2018-12-31 | $158.02 Million | +210.88% |
| 2017-12-31 | $50.83 Million | +180.18% |
| 2016-12-31 | $18.14 Million | +6.23% |
| 2015-12-31 | $17.08 Million | +26.10% |
| 2014-12-31 | $13.54 Million | +311.39% |
| 2013-12-31 | $3.29 Million | -88.72% |
| 2012-12-31 | $29.19 Million | +46.86% |
| 2011-12-31 | $19.88 Million | -- |